Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial

Hum Reprod. 2008 Aug;23(8):1820-9. doi: 10.1093/humrep/den131. Epub 2008 May 15.

Abstract

Background: Temporary exposure of follicles to increased levels of androgens may augment follicular responsiveness. The present study tested whether short-term androgen priming by aromatase inhibitor and human chorionic gonadotrophin (hCG) before controlled ovarian stimulation (COS) increases the number of top-quality embryos after IVF/ICSI.

Methods: Patients were randomized to androgen priming (n = 53): anastrozole 1 mg cycle day (c.d.) 2, 3 and 4, hCG 1250 IU and cetrorelix 3 mg on c.d. 2, rFSH 150 IU from c.d. 5 following a flexible antagonist protocol; or control (n = 50): flexible antagonist protocol.

Results: The mean (confidence interval) number of top-quality embryos was 1.08 (0.83,1.40) and 1.43 (1.12,1.81) in the priming and control group, respectively, being 32% (-7%, 89%) higher in the control compared to priming group (P = 0.120). Stimulation duration was longer in the priming group (P < 0.001). On the day of hCG administration, the proportion of c.d. 2 antral follicles reaching >or=14 mm was higher in the priming group (P = 0.014), as were serum estradiol (E(2)) (P < 0.001) and E(2) per follicle >or=14 mm (P = 0.005). Pre-ovulatory follicular fluid levels of E(2) (P = 0.007) and testosterone (P = 0.014) were higher in the priming group. The number of oocytes retrieved was similar. The fertilization rate was lower in the priming group (P = 0.007). Ongoing pregnancy rates in priming and control group were 30 and 36% (P = 0.531).

Conclusions: Administration of aromatase inhibitor and hCG before COS for IVF/ICSI failed to improve the number of top-quality embryos.

Trial registration: ClinicalTrials.gov NCT00286364.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anastrozole
  • Androgens / physiology*
  • Aromatase Inhibitors / therapeutic use*
  • Chorionic Gonadotropin / therapeutic use*
  • Estradiol / blood
  • Female
  • Fertilization in Vitro
  • Follicle Stimulating Hormone / blood
  • Follicle Stimulating Hormone, Human / therapeutic use
  • Follicular Fluid / chemistry
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Humans
  • Luteinizing Hormone / blood
  • Male
  • Nitriles / therapeutic use*
  • Ovulation Induction / methods*
  • Pregnancy
  • Pregnancy Rate
  • Progesterone / blood
  • Recombinant Proteins / therapeutic use
  • Sperm Injections, Intracytoplasmic
  • Testosterone / blood
  • Triazoles / therapeutic use*

Substances

  • Androgens
  • Aromatase Inhibitors
  • Chorionic Gonadotropin
  • Follicle Stimulating Hormone, Human
  • Nitriles
  • Recombinant Proteins
  • Triazoles
  • Anastrozole
  • Gonadotropin-Releasing Hormone
  • Testosterone
  • Progesterone
  • Estradiol
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • cetrorelix

Associated data

  • ClinicalTrials.gov/NCT00286364